Cyted, a UK-based medical technology company, has been awarded £3.4m in grants to bring more diagnostic tests to NHS patients in primary and community care settings.
The injection of funding from NHS England’s Small Business Research Initiative (SBRI) will enable Cyted to run additional primary care clinics identifying patients suffering from Barrett’s oesophagus. Chronic reflux patients who benefit from the program will be able to have a test in community settings to diagnose Barrett’s esophagus symptoms, without the need to be admitted to hospital.
Because Barrett’s esophagus can progress to esophageal cancer, early diagnosis of the condition helps identify more cancers in the future. The tests allow endoscopies to be prioritized for patients who have signs of early cancer, facilitating triage from waiting lists and reducing pressure on endoscopy services.
The grant comes from the NHS Cancer programme, supported by SBRI Healthcare and Accelerated Access Collaborative, to enable improved efficiency, co-ordination and communication throughout the care pathway for people living with chronic reflux.
The new funding follows a £500,000 SBRI grant awarded last year to Cyted to pilot its trial technology in community care settings in the North West of England. Both grants were awarded as part of Cyted’s work to bring more testing to the community to increase accessibility for people living with chronic reflux and Barrett’s esophagus.
Cyted’s diagnostic platform brings together a non-invasive test with data-driven biomarkers for early detection and risk stratification of cancers and inflammatory diseases. Its first application is in esophageal cancer. Cyted has performed more than 15,000 tests in more than 80 hospitals to diagnose and monitor patients suffering from Barrett’s esophagus to date. Late diagnoses and long wait times for endoscopies can lead to low survival rates. Cyted’s technology helps identify cancer in its early stages when treatment can be most effective.
Cyted CEO Marcel Gehrung said: “Today’s announcement is great news for Cyted and for patients. It means we can test faster and more efficiently in communities and ensure people can receive rapid diagnoses without having to go into hospital We are building a long-standing partnership with the NHS and look forward to expanding this work.
“This substantial grant underscores the global potential of Cyted’s diagnostic technology. Around the world, esophageal cancer is a major global health problem, and our non-invasive test can make a significant contribution to shortening the times of ‘wait and save lives’.
The grant was awarded through an SBRI Healthcare competition. SBRI Healthcare is an NHS England & NHS improvement initiative, supported by the Academic Health Science Network (AHSN) and managed by the LGC Group.
Cyted will be exhibiting in the Med-Tech Innovation Expo Start-Up Zone at stand C32F. Register for FREE at www.med-techexpo.com.
Source link
Ikaroa is delighted to announce that Cyted, a technology company dedicated to offering innovative solutions to diagnose and treat esophageal cancer, has been awarded a £3.4m grant from the Home Office to develop new diagnostics for oesophagus cancer. This development is critical for the early detection and successful treatment of oesophagus cancers, which can have devastating impacts on patients.
Cyted’s new testing technology leverages the latest advances in computer vision, to enable faster and more accurate detection of the disease. This has the potential to enable earlier diagnosis of oesophagus cancers in the community, and reduce the burden of treatable cases that are missed.
The grant has been awarded to Cyted to develop, validate and test its technology in clinical trials. The research team at Cyted includes highly experienced AI and medical imaging specialists, as well as experienced oncologists.
At Ikaroa, we are proud to be alongside Cyted in developing the revolutionary diagnostics technology for oesophagus cancers. We believe that improving early diagnosis is a key part of reducing the burden of the disease, and we look forward to working with Cyted to help improve the lives of patients worldwide.
